Literature DB >> 15814228

Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D,L-lactic-co-glycolic acid) versus chitosan microspheres.

K S Jaganathan1, Y U B Rao, Paramjit Singh, D Prabakaran, Swati Gupta, Anubhav Jain, Suresh P Vyas.   

Abstract

Stable polymeric microspheres capable of controlled release of tetanus toxoid (TT) for periods ranging from days to over months were developed. TT was stabilized, encapsulated in microspheres prepared from poly(D,L)-lactide-co-glycolide (PLGA) and chitosan by using protein stabilizer (trehalose) and its immune response was compared. The influence of co-encapsulated protein stabilizer on tetanus toxoid's stability and release from the microspheres was studied. The protein stabilizer (trehalose) prevented structural losses and aggregation of microencapsulated TT. To neutralize the acids liberated by the biodegradable lactic/glycolic acid-based polymer, we also co-incorporated into the polymer an antacid, (Mg(OH)2), which neutralized the acidity during degradation of the polymer and also prevented TT structural losses and aggregation. The in vitro release experiments with PLGA and chitosan microspheres were performed and the release of TT was increased up to 80-90%. The antigen integrity was investigated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by coomassie brilliant blue staining. The SDS-PAGE analysis confirmed that antigen integrity was not affected by the encapsulation procedure. In addition, the immunogenicity of PLGA and chitosan microspheres based single dose vaccine was evaluated in guinea pigs and compared with multiple doses of alum adsorbed TT. Results indicated that a single injection of PLGA and chitosan microspheres containing TT could maintain the antibody response at a level comparable to the booster injections of conventional alum adsorbed vaccines. The both PLGA and chitosan based stable vaccine formulations produced an equal immune response. Hence chitosan can be used to replace the expensive polymer PLGA. This approach should have potential application in the field of vaccine delivery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814228     DOI: 10.1016/j.ijpharm.2004.12.026

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  13 in total

1.  Formulation of anastrozole microparticles as biodegradable anticancer drug carriers.

Authors:  Ahmed S Zidan; Omaima A Sammour; Mohammed A Hammad; Nagia A Megrab; Muhammad D Hussain; Mansoor A Khan; Muhammad J Habib
Journal:  AAPS PharmSciTech       Date:  2006-07-21       Impact factor: 3.246

2.  Influence of particle size and antacid on release and stability of plasmid DNA from uniform PLGA microspheres.

Authors:  Neelesh K Varde; Daniel W Pack
Journal:  J Control Release       Date:  2007-09-21       Impact factor: 9.776

3.  Nucleic acid aptamers as stabilizers of proteins: the stability of tetanus toxoid.

Authors:  Nishant Kumar Jain; Hardik C Jetani; Ipsita Roy
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

4.  Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis.

Authors:  André C Amaral; Alexandre F Marques; Julián E Muñoz; Anamélia L Bocca; Andreza R Simioni; Antonio C Tedesco; Paulo C Morais; Luiz R Travassos; Carlos P Taborda; Maria Sueli S Felipe
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

5.  Alginate Microencapsulation for Oral Immunisation of Finfish: Release Characteristics, Ex Vivo Intestinal Uptake and In Vivo Administration in Atlantic Salmon, Salmo salar L.

Authors:  Bikramjit Ghosh; Barbara F Nowak; Andrew R Bridle
Journal:  Mar Biotechnol (NY)       Date:  2015-09-26       Impact factor: 3.619

Review 6.  Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.

Authors:  Shujing Wang; Huiqin Liu; Xinyi Zhang; Feng Qian
Journal:  Protein Cell       Date:  2015-05-06       Impact factor: 14.870

7.  Immunogenicity of pulsatile-release PLGA microspheres for single-injection vaccination.

Authors:  Rohiverth Guarecuco; Jennifer Lu; Kevin J McHugh; James J Norman; Lavanya S Thapa; Emily Lydon; Robert Langer; Ana Jaklenec
Journal:  Vaccine       Date:  2017-06-19       Impact factor: 3.641

Review 8.  Overview of new vaccines and technologies.

Authors:  W S K Chalmers
Journal:  Vet Microbiol       Date:  2006-04-18       Impact factor: 3.293

9.  Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine.

Authors:  Stacie J Fairley; Shree R Singh; Abebayehu N Yilma; Alain B Waffo; Praseetha Subbarayan; Saurabh Dixit; Murtada A Taha; Chino D Cambridge; Vida A Dennis
Journal:  Int J Nanomedicine       Date:  2013-05-30

10.  Synergistic Effects of Controlled-Released BMP-2 and VEGF from nHAC/PLGAs Scaffold on Osteogenesis.

Authors:  Ting Wang; Shu Guo; Hua Zhang
Journal:  Biomed Res Int       Date:  2018-09-24       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.